| Migraine |
1 |
1 |
| Tryptamine |
0 |
0.59 |
| Headache |
0 |
0.44 |
| Primary Care |
0 |
0.37 |
| Prophylaxis |
0 |
0.37 |
| Pain Management |
0 |
0.35 |
| Receptors |
0 |
0.29 |
| Angiotensin II Receptor Blockade |
0 |
0.26 |
| Adverse Effects |
0 |
0.22 |
| Pain |
0 |
0.22 |
| Chronic Pain |
0 |
0.21 |
| Neck Pain |
0 |
0.21 |
| Neuropathic Pain |
0 |
0.21 |
| Toxicology |
0 |
0.21 |
| Depression |
0 |
0.19 |
| Hypertension |
0 |
0.19 |
| Cyclic Antidepressants |
0 |
0.17 |
| Patient Safety |
0 |
0.17 |
| Brain |
0 |
0.15 |
| Cardiovascular disease |
0 |
0.15 |
| Sleep |
0 |
0.15 |
| Cardiovascular Risk Management |
0 |
0.11 |
| Electronic Health Record (EHR) |
0 |
0.09 |
| Antidepressant drug |
0 |
0.07 |
| Antihypertensive Agents |
0 |
0.07 |
| Anxiety |
0 |
0.07 |
| Beta-Adrenergic Agonist |
0 |
0.07 |
| Board Certification |
0 |
0.07 |
| Cerebrovascular Disease |
0 |
0.07 |
| Cervical Region |
0 |
0.07 |
| Child |
0 |
0.07 |
| Chronic Headache |
0 |
0.07 |
| Electronic Medical Record |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Monoclonal Antibody |
0 |
0.07 |
| Mood Disorders |
0 |
0.07 |
| Nausea |
0 |
0.07 |
| Nonsteroidal Anti-Inflammatory Agents |
0 |
0.07 |
| Physical Therapy |
0 |
0.07 |
| Steroids |
0 |
0.07 |
| Thorax |
0 |
0.07 |
| Anxiety Disorder |
0 |
0.06 |
| Biologic Therapy |
0 |
0.06 |
| Cerebrovascular Accident |
0 |
0.06 |
| Physical Medicine and Rehabilitation (PMR) |
0 |
0.06 |
| Revenue and Practice Management |
0 |
0.06 |